Brief: TScan Outlines 2022 Priorities As Programs Enter Clinic

Tscan Therapeutics

10/01/2022 12:26

Jan 10 (Reuters) - TScan Therapeutics Inc  TCRX.O :
    * TSCAN OUTLINES 2022 PRIORITIES AS PROGRAMS ENTER CLINIC
    * TSCAN THERAPEUTICS INC - IND SUBMISSIONS COMPLETED IN Q4 2021 FOR LEAD
LIQUID
TUMOR TCR-T CANDIDATES TSC-100 AND TSC-101
    * TSCAN THERAPEUTICS INC - LEAD TCR IDENTIFIED FOR SOLID TUMOR PROGRAM
TARGETING
HPV16
    * TSCAN THERAPEUTICS INC - FURTHER TCRS ADVANCING INTO IND-ENABLING
ACTIVITIES
WITH IND SUBMISSIONS PLANNED FOR SECOND HALF OF 2022
    * TSCAN THERAPEUTICS INC - TSCAN DEVELOPING MULTI-TARGET AND MULTI-HLA
SOLUTION
FOR NON-SMALL-CELL LUNG, CERVICAL, HEAD & NECK CANCERS AND MELANOMA
    * TSCAN THERAPEUTICS INC - AS OF SEPTEMBER 30, 2021, COMPANY HAD CASH AND
CASH
EQUIVALENTS TOTALING $182.9 MILLION
    * TSCAN THERAPEUTICS INC - EXPECTS THAT ITS CASH AND CASH EQUIVALENTS WILL
ENABLE
IT TO FUND ITS OPERATING EXPENSES INTO 2024

Source text for Eikon:  ID:nGNX5ljW6L 
Further company coverage:  TCRX.O